- Rhone-Poulenc Rorer has submitted marketing applications in 13 European Union countries for Campto (irinotecan/CPT-11), its treatment for advanced metastatic colorectal cancer which has failed to respond to standard chemotherapy with 5-flourouracil and folinic acid. The cancer was stabilized in 42% of the 455 patients after a median duration of five months. Side effects include moderate-to-severe diarrhea and neutropenia. The drug was recently approved in the USA where it is licensed to Pharmacia & Upjohn.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze